Booster dosing restored immune responses in rituximab-treated patients who failed primary vaccination
Patients receiving rituximab sit at a difficult intersection of infection risk and vaccine hyporesponsiveness. In this blinded randomized trial, investigators tested whether a third COVID-19 vaccine dose could rescue immunity after a failed primary mRNA series, and whether switching platforms offered any advantage over staying with the same mRNA product. The question was highly specific: among immunosuppressed patients who had not seroconverted after initial vaccination, would a heterologous vector booster outperform a homologous mRNA booster, or would both approaches simply reopen the door to immune priming?
The study enrolled 60 patients under rituximab treatment who had not developed SARS-CoV-2 antibodies after primary vaccination with either BNT162b2 or mRNA-1273. Participants were assigned to receive a third dose using either the same mRNA vaccine or the vector vaccine ChAdOx1 nCoV-19. Randomization was stratified by the presence of peripheral B cells, a biologically sensible choice because B-cell depletion is the central mechanism by which rituximab can blunt antibody formation. When B cells are absent or nearly absent, the vaccine can still stimulate T-cell immunity, but the expected humoral response becomes much harder to achieve.
Antibody seroconversion remained modest, and the two booster strategies looked similar
At week 4, seroconversion rates were numerically low in both groups. Six of 27 patients in the vector arm seroconverted, compared with 9 of 28 in the mRNA arm, a difference that was not statistically significant (p=0.6). Overall, 27% of patients seroconverted after the booster dose. The central practical point is stark: a third dose can rescue antibody formation in a meaningful minority of rituximab-treated patients, but changing vaccine platform did not clearly improve the odds in this cohort.
No signal emerged that the heterologous approach was superior on the primary endpoint. The absence of a clear difference matters because the strategy had biological appeal; a vector vaccine might theoretically broaden immune activation through a distinct antigen-delivery system. In this trial, however, that theoretical advantage did not translate into a better antibody response within 4 weeks.
Peripheral B-cell status separated responders from nonresponders with striking clarity. Only 3 of 37 patients without detectable peripheral B cells seroconverted, whereas 12 of 18 patients with detectable B cells did so. That gap reflects the core immunology of rituximab exposure: if B cells have not repopulated, the machinery needed for antibody generation remains constrained, regardless of whether the booster is delivered as mRNA or vector platform.
Cellular immunity emerged even when antibodies did not
The immune story did not end with antibody testing. T-cell responses were detected in all 20 patients tested in the vector arm and in 13 of 16 patients tested in the mRNA arm. Those findings suggest that even when serologic conversion remains incomplete, vaccination can still trigger cellular immunity in many patients with profound humoral suppression. In a population vulnerable to severe COVID-19, cellular responses may still contribute to protection against progression, even if they cannot be easily translated into a routine antibody assay result.
Newly induced humoral and/or cellular responses occurred in 9 of 11 patients, a high proportion that reinforces the idea that a booster dose can produce some measurable immune gain even after an initial failure. The result is clinically important because it argues against therapeutic nihilism in patients who did not respond to the primary series. A negative antibody test after the first vaccination course does not necessarily mean the immune system is incapable of being educated at all.
Safety findings were reassuring across both vaccine approaches
Safety was assessed at week 1 and week 4, and no serious adverse events related to immunization were observed. For clinicians caring for patients with autoimmune disease or other indications for rituximab, that is not a trivial finding. These patients often arrive with layered concerns: ongoing immunosuppression, prior vaccine failure, and uncertainty about whether another dose will provoke intolerance without benefit. In this trial, neither booster strategy generated a serious safety concern within the observed follow-up window.
The safety profile supports a straightforward bedside message. If a patient on rituximab has failed to seroconvert after a primary mRNA course, another vaccine dose can be considered without strong evidence that switching to ChAdOx1 nCoV-19 will produce a superior antibody response. The choice between heterologous and homologous boosting did not separate itself on efficacy, while the broader immune readout favored giving the additional dose rather than stopping after the failed primary series.
B-cell recovery likely remains the gatekeeper for vaccine success
The biology behind these results is coherent. Rituximab depletes CD20-positive B cells, reducing the body’s ability to generate plasma cells and produce neutralizing antibodies after vaccination. When peripheral B cells begin to reappear, the probability of seroconversion rises sharply, as the study’s subgroup data show. This makes peripheral B-cell monitoring a plausible tool for timing boosters in selected patients, especially when vaccine response is expected to be fragile.
At the same time, the study also shows that immune recovery is not binary. Some patients without detectable peripheral B cells still generated responses, and cellular immunity appeared across both vaccine groups. The clinical implication is subtle but important: the immune system under rituximab is suppressed, not erased. A carefully timed booster may still recruit enough residual immune capacity to matter.
The main limitation is embedded in the outcome itself. The trial was small, and the absolute seroconversion rates were low enough that only large differences would have been easy to detect. Even so, the data do not support a strong preference for heterologous over homologous boosting in this setting. The more actionable signal is simpler: additional vaccination can produce useful immune responses after primary failure, particularly when B cells are detectable and immune reconstitution has begun.